Bhopal’s 3B BlackBio Biotech is second Indian firm to produce COVID-19 testing kits

File photo used for representational purpose.

File photo used for representational purpose.   | Photo Credit: AP

We will try to keep cost below ₹1,000 each, says company official

Bhopal-based 3B Blackbio Biotech (I) Ltd. is going to be the second Indian firm to produce real-time polymerase chain reaction (PCR) COVID-19 testing kits, after securing the approval of the Centre on April 2.

COVID-19 | Interactive map of confirmed coronavirus cases in India

A subsidiary of KILPEST India Ltd., the firm’s production capacity of 10,000 kits a day will give a leg up to testing efforts across the country, after its kits were cleared by the Indian Council of Medical Research. So far, Pune-based Mylab has been supplying kits, besides imports from the United States.

Also read | State-wise tracker for coronavirus cases, deaths and testing rates

“Different States are making inquiries with us, and we are locking them,” said Dhirendra Dubey, Director, Kilpest India Ltd. “Yet, we are trying to devise a policy wherein all States get kits, and none hoards them. Production is expected to begin in a day or two.”

Mr. Dubey further said, “We are trying to keep the [cost of the] kits below ₹1,000 each. And they will be designed according to the World Health Organisation guidelines. A kit can show results within two hours.”

Data | Which States recorded the most coronavirus cases, deaths, and the best testing rates?

The firm’s entire production capacity will be used for producing the kits. “We are using the existing infrastructure as we have been manufacturing molecular diagnostic kits for several years now,” he explains.

According to the kit’s description, it works on any of the available real-time PCR instruments available with laboratories and hence it does not require any new expense on new or closed systems.

The firm in the past had launched India’s first homemade test for another pandemic — H1N1 — commonly known as swine flu.

A letter from the Editor

Dear reader,

We have been keeping you up-to-date with information on the developments in India and the world that have a bearing on our health and wellbeing, our lives and livelihoods, during these difficult times. To enable wide dissemination of news that is in public interest, we have increased the number of articles that can be read free, and extended free trial periods. However, we have a request for those who can afford to subscribe: please do. As we fight disinformation and misinformation, and keep apace with the happenings, we need to commit greater resources to news gathering operations. We promise to deliver quality journalism that stays away from vested interest and political propaganda.

Support Quality Journalism
Related Topics
Recommended for you
This article is closed for comments.
Please Email the Editor

Printable version | May 27, 2020 8:59:18 AM |

Next Story